Alnylam Pharmaceuticals (ALNY) Stock Price, Quote & News

Company Profile

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 551 8200

Fax: 617 551 8101

Website: www.alnylam.com

Address:

675 West Kendall Street, Henri A. Termeer Square, Cambridge, United States

ElliottwaveForecast Sep. 14 at 10:02 AM

📈 $ALNY Alnylam Pharmaceuticals is expected to rally toward the $479–$494 zone to complete wave ((3)) of III. Once this final leg unfolds, a larger wave ((4)) correction could begin. Bulls may look to buy the next pullback in 3, 7, or 11 swings against the April 2025 low. 🔗 https://elliottwave-forecast.com/stock-market/alnylam-alny-rally-479-494-correction-start/ #ElliottWave #Biotech #TradingSetup

0 · Reply

MoneyGroupLLC Sep. 13 at 10:14 AM

Enter: $ALNY OCT 17 2025 $480 CALLS Buy in Price: $17.45 - $20.60 Take Profit: $22.68 Stop Bleeding: $15.36 ROI Potential: 30% Exit Within: 75 Minutes https://moneygroup.us/alerts

0 · Reply

ElliottwaveForecast Sep. 12 at 1:23 AM

🚀 Alnylam $ALNY is showing strong upside momentum, with a projected rally into the $479–$494 zone before a correction sets in. 📈 Dive into the full wave outlook: https://elliottwave-forecast.com/stock-market/alnylam-alny-rally-479-494-correction-start/ Elliott Wave analysis suggests this move could complete the current impulse sequence, setting up a potential buy opportunity on the next pullback in 3, 7, or 11 swings. #ALNY #BiotechStocks #ElliottWave #TradingSetup #MarketOutlook

0 · Reply

Thepatientone Sep. 11 at 6:12 PM

$ABUS - Shorts need to return borrowed shares ASAP. There is nothing stopping this bus from collecting payments from $MRNA. $PFE, $BNTX, $ALNY and declaring FC rate above 60% on HBV....

0 · Reply

anachartanalyst Sep. 11 at 4:02 PM

$ALNY https://anachart.com/wp-content/uploads/ana_temp/1757606506_soc-img.jpg

0 · Reply

JarvisFlow Sep. 11 at 1:51 PM

Evercore ISI Group updates rating for Alnylam Pharmaceuticals ( $ALNY ) to Outperform, target set at 280 → 515.05.

0 · Reply

ElliottwaveForecast Sep. 11 at 11:16 AM

Alnylam $ALNY 🚀 Expected to rally into the $479–$494 zone before a correction kicks in. See the full Elliott Wave outlook here 👉 https://elliottwave-forecast.com/stock-market/alnylam-alny-rally-479-494-correction-start/ #Elliottwave #Trading

0 · Reply

ElliottwaveForecast Sep. 10 at 6:03 PM

Is ALNY setting up for another big move? 🚀 Check out the full analysis 👉 ALNY Elliott Wave Forecast: https://elliottwave-forecast.com/stock-market/alnylam-alny-rally-479-494-correction-start/ Alnylam Pharmaceuticals $ALNY rallied over 40% from its April 2025 low and now targets the $479–$494 zone to complete wave ((3)). A pullback in wave ((4)) is expected next—ideal for traders watching the 3-7-11 swing setup. Understand the Elliott Wave structure and how to forecast the next leg with precision. #ALNY #Biotech #ElliottWave #Stocks #Trading #Forecast

0 · Reply

Jadek6 Sep. 10 at 12:37 PM

$CADL $NTLA $AGIO $QURE ..poor example to use !!! He was a loser in that series Could have arrested Bobby, right away , but like me, he GOT AWAY …the LOSERS NEVER MOVE FAST ENOUGH AGAINST THE WINNERS … TAK ..is still screaming like Rhoades , but no one pays attention to a washed up, no clout, CEO !!! GSK even said ..GOOD BYE.. sympathies to @Drizz Open up your wallet to $ALNY , hahahah, a winner for 6 years straight , why ???? NO TAK

0 · Reply

ElliottwaveForecast Sep. 9 at 10:02 PM

$ALNY isn’t done yet—but the easy move might be. A choppy (4) pullback is likely before the final push toward 479–494 to complete the April 2025 cycle. Check out Free latest article 👉 https://elliottwave-forecast.com/stock-market/alnylam-alny-rally-479-494-correction-start/ #Elliottwave #Stocks

0 · Reply

Alnylam Pharmaceuticals, Inc. (ALNY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 11:16 PM EDT - 4 days ago

Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes

Sep 8, 2025, 4:15 PM EDT - 5 days ago

Alnylam Announces Proposed Offering of $500 Million Convertible Senior Notes

Sep 3, 2025, 4:58 PM EDT - 10 days ago

Alnylam Pharmaceuticals, Inc. (ALNY) Presents At Citi's Biopharma Back To School Conference Prepared Remarks Transcript

Sep 3, 2025, 12:56 AM EDT - 11 days ago

Alnylam Pharmaceuticals: Amvuttra's Launch And Ongoing Clinical Progress Are Positives

Aug 31, 2025, 5:15 AM EDT - 14 days ago

New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran's Long-Term Cardiovascular Benefit in ATTR-CM

Aug 30, 2025, 10:30 AM EDT - 14 days ago

Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension

Aug 30, 2025, 10:30 AM EDT - 14 days ago

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial

Aug 28, 2025, 6:20 AM EDT - 17 days ago

mRNA Biotechs - Long-Term Value Risks Abound

BNTX DHR GRAL ILMN IONS MRNA RGEN

Aug 27, 2025, 8:00 AM EDT - 18 days ago

Alnylam to Webcast Presentations at Upcoming September Investor Conferences

Aug 26, 2025, 5:00 AM EDT - 19 days ago

Scenic Enters License and Research Agreement with Alnylam

Aug 11, 2025, 8:00 AM EDT - 4 weeks ago

Alnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025

Aug 5, 2025, 8:00 AM EDT - 5 weeks ago

Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference

Aug 1, 2025, 2:28 PM EDT - 6 weeks ago

Alnylam's Amvuttra Makes Powerful Entrance, Eyes First-Line Dominance

Aug 1, 2025, 8:31 AM EDT - 6 weeks ago

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

ABBV ABT AMGN ARGX AZN BAX BIIB

Aug 1, 2025, 6:54 AM EDT - 6 weeks ago

President Trump demands drugmakers slash prices within 60 days

ABBV ABT AMGN ARGX AZN BAX BIIB

Jul 31, 2025, 4:47 PM EDT - 6 weeks ago

Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 3:36 PM EDT - 6 weeks ago

Alnylam Pharmaceuticals Q2 Earnings Crush Estimates, Stock Hits 52-Week High On Upbeat Forecast

Jul 31, 2025, 3:13 PM EDT - 6 weeks ago

Alnylam: Amvuttra Is Just Getting Started

Jul 31, 2025, 8:00 AM EDT - 6 weeks ago

Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress

Jul 23, 2025, 9:57 AM EDT - 7 weeks ago

Five years after COVID, pharma shares languish in US policy limbo

ABBV ABT AZN EW LLY MRK NVO

Jul 17, 2025, 8:00 AM EDT - 2 months ago

Alnylam to Webcast Conference Call Discussing Second Quarter 2025 Financial Results

Jul 1, 2025, 9:06 AM EDT - 2 months ago

Alnylam Pharma Stock Outlook: Is ALNY Topping Out?

Jun 18, 2025, 12:04 PM EDT - 3 months ago

Alnylam Pharmaceuticals Names Garg R&D Chief

Jun 18, 2025, 10:05 AM EDT - 3 months ago

Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer

Jun 9, 2025, 6:00 AM EDT - 3 months ago

Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy

May 28, 2025, 8:00 AM EDT - 3 months ago

Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference

May 20, 2025, 9:00 AM EDT - 4 months ago

Alnylam Issues 2024 Corporate Responsibility Report

May 17, 2025, 5:50 AM EDT - 4 months ago

AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B

May 12, 2025, 7:00 AM EDT - 4 months ago

Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress

May 5, 2025, 10:00 AM EDT - 4 months ago

Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference

May 1, 2025, 1:11 PM EDT - 4 months ago

Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2025 Earnings Call Transcript

May 1, 2025, 8:00 AM EDT - 4 months ago

Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress

Apr 28, 2025, 8:00 AM EDT - 4 months ago

Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Apr 17, 2025, 8:00 AM EDT - 5 months ago

Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results

Apr 1, 2025, 8:00 AM EDT - 5 months ago

Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference

Mar 31, 2025, 2:05 PM EDT - 5 months ago

Stifel's Paul Matteis says look for biotech names not dependent on the FDA amid sector uncertainty

XBI RYTM VRTX XENE

Mar 29, 2025, 1:00 PM EDT - 6 months ago

Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology's Annual Scientific Session 2025

Mar 28, 2025, 4:44 PM EDT - 6 months ago

FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B

Mar 28, 2025, 7:14 AM EDT - 6 months ago

siRNA Gene Silencing Market Landscape Report 2025: United States and Ireland Stand Out with 2 Major M&A Deals Worth $54.9 Billion, Alnylam Pharmaceuticals Leads the Way with 79 Trials

Mar 24, 2025, 2:08 PM EDT - 6 months ago

Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades Stock

Mar 21, 2025, 5:37 PM EDT - 6 months ago

Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster

Mar 21, 2025, 10:00 AM EDT - 6 months ago

Alnylam's Amvuttra Secures FDA Approval For Expanded Use For Rare Heart Disease, Stock Jumps

Mar 21, 2025, 7:34 AM EDT - 6 months ago

Alnylam shares rise on expanded heart drug approval

Mar 20, 2025, 5:59 PM EDT - 6 months ago

US FDA approves Alnylam's drug for rare heart condition

Mar 20, 2025, 5:54 PM EDT - 6 months ago

Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

Mar 11, 2025, 8:00 AM EDT - 6 months ago

Alnylam to Webcast Presentation at Stifel 2025 Virtual CNS Forum

Mar 5, 2025, 7:00 AM EST - 6 months ago

Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary

Feb 25, 2025, 7:00 AM EST - 7 months ago

Alnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D Day

Feb 13, 2025, 5:01 PM EST - 7 months ago

Alnylam: Waiting For Regulatory Updates In March

ElliottwaveForecast Sep. 14 at 10:02 AM

0 · Reply

MoneyGroupLLC Sep. 13 at 10:14 AM

Enter: $ALNY OCT 17 2025 $480 CALLS Buy in Price: $17.45 - $20.60 Take Profit: $22.68 Stop Bleeding: $15.36 ROI Potential: 30% Exit Within: 75 Minutes https://moneygroup.us/alerts

0 · Reply

ElliottwaveForecast Sep. 12 at 1:23 AM

0 · Reply

Thepatientone Sep. 11 at 6:12 PM

$ABUS - Shorts need to return borrowed shares ASAP. There is nothing stopping this bus from collecting payments from $MRNA. $PFE, $BNTX, $ALNY and declaring FC rate above 60% on HBV....

0 · Reply

anachartanalyst Sep. 11 at 4:02 PM

$ALNY https://anachart.com/wp-content/uploads/ana_temp/1757606506_soc-img.jpg

0 · Reply

JarvisFlow Sep. 11 at 1:51 PM

Evercore ISI Group updates rating for Alnylam Pharmaceuticals ( $ALNY ) to Outperform, target set at 280 → 515.05.

0 · Reply

ElliottwaveForecast Sep. 11 at 11:16 AM

0 · Reply

ElliottwaveForecast Sep. 10 at 6:03 PM

0 · Reply

Jadek6 Sep. 10 at 12:37 PM

0 · Reply

ElliottwaveForecast Sep. 9 at 10:02 PM

0 · Reply

THE_Monkey_Banana_Genius Sep. 9 at 5:59 PM

$ALNY $ARGX $MDGL $VRTX damn. Too bad i was a 🦐 biscuit and got shaken out. Lame

1 · Reply

ElliottwaveForecast Sep. 9 at 4:23 AM

0 · Reply

ElliottwaveForecast Sep. 9 at 4:10 AM

Missed the $ALNY rally? Here’s how we saw it coming. Back in 7.14.2025 update, it called for upside from the #bluebox (April 2025 low) toward 368–469 in wave ((3)) using #Elliottwave. It hit the target. What’s next for $ALNY?

0 · Reply

DonCorleone77 Sep. 8 at 9:18 PM

$ALNY Alnylam announces $500M convertible senior notes offering

0 · Reply

johnnygogogo Sep. 8 at 8:29 PM

$ALNY oh look, a new convertible @skeezbag @Pantherfan7979

0 · Reply

ZacksResearch Sep. 8 at 2:59 PM

$ALNY up 92.1% YTD — is there more room to run? Amvuttra sales surged 89% YoY, driving top-line growth. Key collaborations with Regeneron and Roche. 2025 EPS estimates have improved from $1.20 to $3.66 in the past 60 days. Discover the full investment case here 👉 https://www.zacks.com/stock/news/2747931/can-alnys-key-partnerships-with-pharma-giants-drive-long-term-growth?cid=sm-stocktwits-2-2747931-body-11333&ADID=SYND_STOCKTWITS_TWEET_2_2747931_BODY_11333

0 · Reply

IN0V8 Sep. 8 at 2:42 PM

$ALNY BMO raises target price to $470 from $450

0 · Reply

ZacksResearch Sep. 8 at 1:44 PM

$ALNY — Partnerships or profits? Strong drug sales plus advancing deals with Regeneron and Roche are positioned as the key drivers for growth in upcoming quarters. Find out if ALNY’s long-term story is built to last 👉 https://www.zacks.com/stock/news/2747931/can-alnys-key-partnerships-with-pharma-giants-drive-long-term-growth?cid=sm-stocktwits-2-2747931-teaser-11286&ADID=SYND_STOCKTWITS_TWEET_2_2747931_TEASER_11286

0 · Reply

JarvisFlow Sep. 8 at 12:00 PM

BMO Capital has updated their rating for Alnylam Pharmaceuticals ( $ALNY ) to Outperform with a price target of 470.

0 · Reply

angelinvesting369 Sep. 7 at 7:28 PM

$REGN $NTLA $ALNY with the amyloidosis franchise is a probable buyer of Intellia too

0 · Reply

Fingerlickengood Sep. 7 at 6:54 PM

$CDXS $ALNY $RHHBY https://www.biotechtv.com/post/corsera-health-john-maraganore

3 · Reply

Fingerlickengood Sep. 7 at 6:48 PM

$CDXS $ALNY $RHHBY This statement from the attached article stands out to me regarding Corsera Health, "With a preventive RNAi medicine expected to enter the clinic by the end of 2025, administered once-annually and priced to enable broad access, Corsera Health aims to prevent cumulative cardiovascular damage and support longer, healthier lives." This suggests they possibly have acquired something nearing or already FDA approved. What exactly is that is yet to be seen! https://www.streetinsider.com/dr/news.php?id=25280745

0 · Reply

Market Cap	61.07B
Revenue (ttm)	2.25B
Net Income (ttm)	-278.16M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	802.95
Profit Margin	-12.37%
Debt to Equity Ratio	0.00

Volume	630,700
Avg Vol	1,160,772
Day's Range	N/A - N/A
Shares Out	131.08M
Stochastic %K	57%
Beta	0.32
Analysts	Strong Sell
Price Target	$452.37